Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 1,500 shares, a decrease of 70.0% from the March 31st total of 5,000 shares. Based on an average daily trading volume, of 13,900 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Cocrystal Pharma in a research note on Thursday, April 4th.

Cocrystal Pharma Stock Up 3.0 %

NASDAQ COCP traded up $0.04 on Friday, reaching $1.56. The company had a trading volume of 29,490 shares, compared to its average volume of 13,389. The stock has a market capitalization of $15.81 million, a PE ratio of -0.78 and a beta of 1.34. The firm’s 50 day moving average price is $1.49 and its 200 day moving average price is $1.63. Cocrystal Pharma has a 12 month low of $1.33 and a 12 month high of $3.29.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Thursday, March 28th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.13. On average, research analysts expect that Cocrystal Pharma will post -2.31 EPS for the current year.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.